For the quarter ending 2026-03-31, GILD has $56,278M in assets.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 7,628 | 7,564 | 7,330 | 5,144 |
| Short-term marketable debt securities | 15 | 68 | 19 | 69 |
| Accounts receivable, net | 4,741 | 4,913 | 5,095 | 4,781 |
| Inventories | 1,914 | 1,774 | 1,785 | 1,825 |
| Prepaid and other current assets | 4,342 | 4,024 | 3,645 | 2,899 |
| Total current assets | 18,641 | 18,342 | 17,874 | 14,718 |
| Property, plant and equipment, net | 5,638 | 5,606 | 5,500 | 5,459 |
| Long-term marketable debt securities | 983 | 2,974 | 2,005 | 1,913 |
| Intangible Asset Sofosbuvir | - | - | 10,720 | - |
| Axicabtageneciloleucel DLBCL | - | - | 7,110 | - |
| Trodelvy | - | - | 11,730 | - |
| Hepcludex | - | - | 845 | - |
| Other Intangible Assets | - | - | 1,479 | - |
| Finite Lived Intangible Assets Gross | - | - | 31,884 | - |
| Finite Lived Intangible Assets Net | 14,082 | 14,678 | - | 15,866 |
| Gross carrying amount | 2,300 | 2,300 | 2,700 | 2,700 |
| Gross carrying amount | - | - | 34,584 | - |
| Accumulated amortization | - | - | 16,614 | - |
| Intangible Asset Sofosbuvir | - | - | 0 | - |
| Axicabtageneciloleucel DLBCL | - | - | 0 | - |
| Trodelvy | - | - | 0 | - |
| Hepcludex | - | - | 0 | - |
| Other Intangible Assets | - | - | 0 | - |
| Finite Lived Intangible Assets Foreign Currency Translation Gain Loss Cumulative Gain Loss | - | - | 0 | - |
| Foreign currency translation adjustment | 0 | 0 | 0 | 0 |
| Total Indefinite Lived Intangible Assets Excluding Goodwill | 2,300 | 2,300 | - | 2,700 |
| Intangible assets, net | 16,382 | 16,978 | 17,970 | 18,566 |
| Goodwill | 8,314 | 8,314 | 8,314 | 8,314 |
| Deferred tax assets | 1,767 | 1,964 | 1,998 | 2,721 |
| Other long-term assets | 4,554 | 4,845 | 4,873 | 4,031 |
| Total assets | 56,278 | 59,023 | 58,533 | 55,721 |
| Accounts payable | 645 | 715 | 808 | 582 |
| Accrued rebates | 4,118 | 4,337 | 4,931 | 4,215 |
| Current portion of long-term debt, net | 1,313 | 2,807 | 2,806 | 2,806 |
| Other current liabilities | 3,399 | 3,953 | 3,752 | 3,586 |
| Total current liabilities | 9,476 | 11,813 | 12,298 | 11,189 |
| Long-term debt, net | 20,861 | 22,129 | 22,135 | 22,140 |
| Long-term income taxes payable | 918 | 896 | 866 | 859 |
| Deferred tax liabilities | 392 | 402 | 597 | 652 |
| Other long-term liabilities | 1,200 | 1,165 | 1,182 | 1,290 |
| Common stock, par value 0.001 per share 5,600 shares authorized 1,242 and 1,241 shares issued and outstanding, respectively | 1 | 1 | 1 | 1 |
| Additional paid-in capital | 9,305 | 8,932 | 8,678 | 8,367 |
| Accumulated other comprehensive income | 78 | 39 | 36 | -18 |
| Retained earnings | 14,131 | 13,730 | 12,825 | 11,325 |
| Total gilead stockholders equity | 23,515 | 22,703 | 21,540 | 19,674 |
| Noncontrolling interest | -84 | -84 | -84 | -84 |
| Total stockholders equity | 23,431 | 22,618 | 21,456 | 19,590 |
| Total liabilities and stockholders equity | 56,278 | 59,023 | 58,533 | 55,721 |
GILEAD SCIENCES, INC. (GILD)
GILEAD SCIENCES, INC. (GILD)